NRDL outlook survey
1.
What is your read of the 2020 NRDL overall?
Exciting
Depressing
Not sure
Please provide rationale.
2.
Is the number of new additions of 119 in line with your expectations?
More than expected
Less than expected
More or less in line
Please provide rationale.
3.
Is the average price cut magnitude of 51% in line with your expectation?
More than expected
Less than expected
More or less in line
Please provide rationale.
4.
What do you see as the key success factors for 2020 NRDL inclusion?
Internal alignment and preparation
Key stakeholder engagements
Price concession magnitude
Clinical value of the drug
Social economic value of the drug
Others
Please provide rationale.
5.
Who do you see as the key stakeholders for 2020 NRDL inclusion besides the NHSA (National Healthcare Security Administration)
Shortlist review experts: Generalists (综合组评审专家)
Shortlist review experts: Clinicians (临床组评审专家)
Pharmacoeconomics evaluation experts (药物经济学组专家)
Budget impact evaluation experts (基金测算专家)
Negotiation experts (谈判专家)
Others
Please provide rationale.
6.
What do you see as the most important evidences needed to be furnished for 2020 NRDL inclusion?
IRP (International reference pricing)
TA (therapeutic area) comparator reference
Clinical data
HEOR data (e.g. ICER, QALY, RWE)
Budget impact data
Others
Please provide rationale.
7.
What new payment models are likely to emerge in future NRDL?
Outcome based pricing
Total cost capping
Patient number capping
Cost capping per patient
DRG
Others
Please provide rationale.
8.
What are the keys for internal alignment and preparations?
Organization effectiveness
Clear roles and responsibilities
Process efficiency
Global and China alignment
Competence and expertise
Others
Please provide rationale.
9.
Your email to receive our analysis
Current Progress,
0 of 9 answered